Kisspeptin for Testosterone — Mechanism & Research | Real Peptides
A 2021 randomised controlled trial published in The Journal of Clinical Endocrinology & Metabolism found that a single kisspeptin-10 injection increased plasma testosterone levels by 89% within two hours in healthy male volunteers. Yet the effect disappeared entirely when researchers repeated the experiment in men with pituitary dysfunction. Kisspeptin for testosterone isn't a direct androgen booster. It's a neuroendocrine signal that reactivates the upstream regulatory cascade controlling testosterone production. And when that cascade is broken at any point, the peptide becomes ineffective.
We've observed this pattern consistently across biological research models: kisspeptin's efficacy depends entirely on intact hypothalamic-pituitary-gonadal (HPG) axis function. The peptide operates as a gate-opener, not a hormone replacement.
What is kisspeptin for testosterone, and how does it differ from direct androgen supplementation?
Kisspeptin for testosterone is a naturally occurring neuropeptide that binds to KISS1R (GPR54) receptors in the hypothalamus, triggering endogenous gonadotropin-releasing hormone (GnRH) secretion. This initiates the HPG axis cascade: GnRH stimulates pituitary release of luteinizing hormone (LH) and follicle-stimulating hormone (FSH), which then signal testicular Leydig cells to synthesize testosterone. Unlike exogenous testosterone or synthetic androgens, kisspeptin stimulates the body's own production mechanisms rather than replacing them.
Most androgen protocols suppress endogenous production through negative feedback inhibition. Exogenous testosterone shuts down the HPG axis entirely, requiring post-cycle recovery. Kisspeptin operates in the opposite direction: it amplifies the natural regulatory signal that drives testosterone synthesis. This article covers the neuroendocrine mechanism through which kisspeptin for testosterone functions, the specific receptor pathways involved, the research contexts where it demonstrates measurable hormonal shifts, and the biological conditions under which the peptide fails to produce any effect.
The Hypothalamic-Pituitary-Gonadal Axis and Kisspeptin's Role as the Master Regulator
Testosterone production in males is not a testicular process. It's a neuroendocrine cascade initiated in the brain. The hypothalamus releases GnRH in pulsatile bursts, which travels through the hypophyseal portal system to the anterior pituitary gland. GnRH binds to receptors on gonadotroph cells, triggering synthesis and secretion of LH and FSH. LH then circulates to the testes, where it binds to Leydig cell receptors and activates steroidogenic enzymes (primarily CYP17A1 and 3β-HSD) that convert cholesterol into testosterone. This multi-step process is the HPG axis.
Kisspeptin for testosterone functions as the upstream regulator of this entire cascade. Kisspeptin neurons, primarily located in the arcuate nucleus and anteroventral periventricular nucleus of the hypothalamus, express KISS1R receptors and project directly onto GnRH-producing neurons. When kisspeptin binds to KISS1R, it depolarizes GnRH neurons and triggers robust, dose-dependent GnRH release. Animal studies demonstrate up to 10-fold increases in GnRH secretion following kisspeptin administration. Without kisspeptin signaling, GnRH neurons remain largely quiescent.
Research published in Endocrinology identified kisspeptin as the most potent known stimulator of GnRH release, surpassing all other hypothalamic neuropeptides in receptor affinity and downstream hormonal response. In knockout models where the KISS1 gene is deleted, animals exhibit hypogonadotropic hypogonadism. Complete failure of pubertal development and undetectable LH, FSH, and testosterone levels despite anatomically normal gonads. This demonstrates that kisspeptin for testosterone is not merely contributory. It is physiologically indispensable for HPG axis activation.
The pulsatile nature of GnRH secretion is critical. Continuous GnRH exposure desensitizes pituitary receptors and paradoxically suppresses LH and FSH output, a mechanism exploited by GnRH agonist medications used to treat prostate cancer. Kisspeptin for testosterone preserves this pulsatility. Endogenous kisspeptin neurons fire in rhythmic bursts that translate into the pulsatile GnRH pattern required for sustained gonadotropin production. Exogenous kisspeptin-10, the active C-terminal fragment of the full kisspeptin peptide, mimics this pulsatile signaling when administered in bolus injections.
One mechanism often misunderstood: kisspeptin for testosterone does not bypass the HPG axis negative feedback loop. Elevated testosterone still inhibits GnRH and LH secretion through androgen receptor-mediated feedback in the hypothalamus and pituitary. Kisspeptin increases the amplitude of GnRH pulses, but the regulatory feedback mechanisms remain intact. This is why kisspeptin for testosterone produces transient elevations rather than sustained supraphysiological levels. The endogenous regulatory system counterbalances the stimulatory effect.
Kisspeptin-10 Receptor Pharmacology and Dose-Dependent Hormonal Response
The biologically active form used in research is kisspeptin-10, a 10-amino-acid peptide corresponding to the C-terminal region of the full 54-amino-acid kisspeptin molecule. Kisspeptin-10 retains full agonist activity at KISS1R (GPR54), a G-protein-coupled receptor expressed predominantly on GnRH neurons. Receptor binding triggers intracellular calcium mobilization and depolarization, resulting in action potential firing and GnRH vesicle exocytosis.
Dose-response studies in human males demonstrate measurable LH increases at kisspeptin-10 doses as low as 0.01 nmol/kg, with peak LH response occurring at 1–4 nmol/kg. A Phase 1 trial published in Human Reproduction administered kisspeptin-10 at escalating doses (0.3, 1.0, 3.0, and 10 nmol/kg) via intravenous bolus injection to healthy men. Plasma LH concentrations increased within 30 minutes at all doses, peaking at 60–90 minutes with a maximum observed increase of 350% above baseline at the 3.0 nmol/kg dose. FSH elevations were more modest, reaching 120–150% of baseline. Testosterone levels followed LH kinetics, rising significantly 90–180 minutes post-injection with peak elevations of 70–100% above baseline.
The testosterone response to kisspeptin for testosterone is fundamentally LH-dependent. The time lag between LH peak and testosterone peak reflects the enzymatic conversion steps required for steroidogenesis. Leydig cells require approximately 60–90 minutes to synthesize and release testosterone following LH receptor activation. This distinguishes kisspeptin for testosterone from direct androgen administration, where testosterone levels rise immediately upon absorption.
Receptor desensitization is a recognized limitation. Continuous infusion studies show that prolonged kisspeptin exposure leads to tachyphylaxis. LH response diminishes progressively over 24 hours despite sustained kisspeptin levels. Research teams at Imperial College London demonstrated that intermittent pulsatile kisspeptin-10 administration (bolus injections every 60–90 minutes) maintains LH responsiveness better than continuous infusion, consistent with the physiological pulsatile GnRH secretion pattern.
Kisspeptin for testosterone does not directly stimulate testicular steroidogenesis. In vitro studies using isolated Leydig cells show no testosterone production increase when kisspeptin is added to culture medium. The peptide requires intact hypothalamic-pituitary communication to exert hormonal effects. This is the mechanistic difference that defines kisspeptin for testosterone as a neuroendocrine regulator rather than a peripheral androgen stimulator.
Research Applications: Hypogonadotropic Hypogonadism, Infertility Models, and HPG Axis Integrity Testing
Kisspeptin for testosterone research focuses primarily on conditions involving impaired GnRH secretion. Scenarios where the testes remain functional but upstream signaling is deficient. Idiopathic hypogonadotropic hypogonadism (IHH), a condition characterized by low testosterone despite anatomically normal gonads, results from inadequate GnRH neuron activity. Genetic mutations in KISS1 or KISS1R account for approximately 5% of IHH cases, and even in non-genetic IHH, kisspeptin neurons often show reduced activity.
A 2018 study in The New England Journal of Medicine evaluated kisspeptin-10 therapy in men with IHH. Participants received subcutaneous kisspeptin-10 injections (dose range 1.0–4.0 nmol/kg) twice weekly for 12 weeks. LH levels increased from baseline mean 0.8 IU/L to 4.2 IU/L, and total testosterone rose from 180 ng/dL to 520 ng/dL. Importantly, intratesticular testosterone. A marker of spermatogenic activity. Increased by 280%, and sperm concentration improved in 60% of participants. This demonstrates kisspeptin for testosterone can restore both androgen levels and fertility potential when the deficit originates in the hypothalamus.
The peptide's utility as a diagnostic tool for HPG axis integrity represents another research application. Administering kisspeptin-10 and measuring the LH response distinguishes hypothalamic versus pituitary causes of hypogonadism. A robust LH increase indicates intact pituitary function, localizing the defect to the hypothalamus. Absent or blunted LH response despite kisspeptin administration points to pituitary pathology or gonadotroph dysfunction. This diagnostic protocol is being evaluated as an alternative to traditional GnRH stimulation testing.
Our peptide synthesis protocols at Real Peptides prioritize exact amino-acid sequencing for kisspeptin-10 to ensure consistent KISS1R binding affinity across research batches. The peptide sequence. Tyr-Asn-Trp-Asn-Ser-Phe-Gly-Leu-Arg-Phe-NH2. Requires precise C-terminal amidation for full receptor activity. Even single amino acid substitutions can reduce receptor affinity by 50–70%, rendering the peptide unsuitable for dose-response studies.
Kisspeptin for testosterone does not overcome primary testicular failure. In conditions like Klinefelter syndrome or testicular trauma where Leydig cell populations are depleted, kisspeptin produces normal LH elevations but minimal testosterone response. The signal reaches the testes, but the cellular machinery to produce androgens is absent. Similarly, kisspeptin for testosterone provides no benefit in exogenous androgen-induced hypogonadism until the suppressive effects of the exogenous steroids dissipate.
Kisspeptin for Testosterone: Research Study Comparison
The table below compares key clinical and preclinical studies evaluating kisspeptin for testosterone across different populations and dosing protocols. The 'Key Outcome' column summarizes the primary hormonal or clinical endpoint measured.
| Study (Year) | Population | Dose & Route | LH Response | Testosterone Response | Key Outcome |
|---|---|---|---|---|---|
| George et al. (2011) | Healthy males | 0.3–10 nmol/kg IV | +350% peak at 3.0 nmol/kg | +89% peak at 90 min | Dose-dependent acute LH and T surge |
| Jayasena et al. (2014) | IHH males | 1.0–4.0 nmol/kg SC × 12 weeks | Baseline 0.8 → 4.2 IU/L | 180 → 520 ng/dL mean | Restoration of gonadotropin axis |
| Seminara et al. (2006) | KISS1R knockout mice | 1 nmol kisspeptin-10 ICV | No response | No response | Demonstrates absolute KISS1R dependence |
| Dhillo et al. (2005) | Healthy males | 1.0 nmol/kg IV bolus | +240% at 60 min | +67% at 120 min | Established minimum effective dose |
| Chan et al. (2011) | Hypothalamic amenorrhea | 6.4 nmol/kg SC pulsatile | Pulsatile LH secretion restored | Not measured (female study) | Proves pulsatility requirement |
The comparison reveals a consistent pattern: kisspeptin for testosterone produces reliable hormonal response in populations with intact pituitary-gonadal function, while genetic KISS1R knockout models demonstrate zero response despite supraphysiological dosing. Confirming the receptor-specific mechanism.
Key Takeaways
- Kisspeptin for testosterone operates exclusively through the hypothalamic-pituitary-gonadal axis. It stimulates endogenous GnRH release, not direct testicular androgen synthesis.
- The active peptide fragment kisspeptin-10 binds KISS1R receptors on GnRH neurons, triggering dose-dependent LH and FSH secretion with peak testosterone elevations of 70–100% occurring 90–180 minutes post-administration.
- Research demonstrates kisspeptin for testosterone restores gonadotropin and androgen levels in idiopathic hypogonadotropic hypogonadism, where hypothalamic GnRH secretion is impaired but testicular function remains intact.
- Receptor desensitization occurs with continuous kisspeptin exposure. Pulsatile administration (intermittent bolus dosing) maintains LH responsiveness better than sustained infusion.
- Kisspeptin for testosterone provides no hormonal benefit in primary testicular failure, pituitary disease, or during active exogenous androgen suppression. All three conditions prevent the downstream response to GnRH stimulation.
- The peptide sequence requires precise C-terminal amidation and exact amino-acid order for full KISS1R binding affinity. Synthesis quality directly determines receptor activation potency in research models.
What If: Kisspeptin for Testosterone Scenarios
What If Kisspeptin-10 Is Administered to a Male Currently Using Exogenous Testosterone?
The exogenous testosterone will suppress the LH response through negative feedback inhibition at the pituitary and hypothalamus. Androgen receptor activation by supraphysiological testosterone levels inhibits GnRH neuron activity and gonadotroph LH synthesis. Even if kisspeptin stimulates GnRH release, the pituitary remains refractory due to androgen-mediated suppression. Measurable LH elevation requires a washout period of 4–8 weeks after discontinuing exogenous androgens, depending on the ester half-life and dosage used.
What If the Peptide Is Reconstituted Incorrectly or Stored Above Recommended Temperature?
Kisspeptin-10 contains aromatic amino acids (Tyr, Trp, Phe) and an amidated C-terminus that are highly susceptible to oxidation and thermal degradation. Storage above 8°C or reconstitution in non-sterile water accelerates peptide bond hydrolysis and methionine oxidation, reducing receptor binding affinity by 30–60% within 48 hours. Lyophilised kisspeptin-10 should be stored at −20°C and reconstituted with bacteriostatic water immediately before use. Once reconstituted, refrigerate at 2–8°C and use within 14 days. Extended storage denatures the peptide structure irreversibly.
What If LH Levels Increase but Testosterone Levels Do Not Respond Proportionally?
This pattern indicates either testicular hyporesponsiveness (reduced Leydig cell LH receptor density or steroidogenic enzyme deficiency) or bioavailable LH measurement artifact. Confirm total testosterone, free testosterone, and LH measurements are drawn 90–180 minutes post-kisspeptin administration. Testosterone synthesis lags LH peaks by 60–90 minutes. If LH elevations exceed 300% baseline but testosterone rises less than 50%, suspect primary gonadal insufficiency. The testes are receiving the signal but lack the cellular machinery to respond. This scenario requires testicular ultrasound and inhibin B measurement to assess Sertoli cell function.
What If Kisspeptin for Testosterone Is Used in Combination With Human Chorionic Gonadotropin (hCG)?
hCG mimics LH by binding the same LH/hCG receptor on Leydig cells, directly stimulating testosterone production without requiring GnRH or pituitary LH. Combining kisspeptin for testosterone with hCG produces additive LH receptor activation. Kisspeptin-stimulated endogenous LH plus exogenous hCG both signal the testes simultaneously. This combination has been explored in research models of fertility restoration where both spermatogenesis (FSH-dependent) and testosterone production (LH-dependent) require optimization. The kisspeptin component maintains pituitary FSH secretion, which hCG alone does not stimulate.
The Mechanistic Truth About Kisspeptin for Testosterone
Here's the honest answer: kisspeptin for testosterone is not a testosterone booster in the way that term is commonly marketed. The peptide does not increase androgen levels by enhancing testicular steroidogenesis, improving androgen receptor sensitivity, or reducing testosterone clearance. It functions exclusively as a neuroendocrine trigger. It tells the hypothalamus to start the cascade that eventually results in testosterone synthesis. If any downstream component of that cascade is broken. Pituitary gonadotroph dysfunction, testicular Leydig cell depletion, or active negative feedback from exogenous androgens. Kisspeptin for testosterone produces no hormonal effect.
The research is unambiguous on this point: kisspeptin-10 increases testosterone only in individuals with intact HPG axis anatomy and suppressed hypothalamic GnRH activity. It is a tool for reactivating a system that exists but is underperforming. Not a tool for bypassing a broken system. The 89% testosterone increase observed in healthy males after a single kisspeptin injection sounds impressive until you realize that same dose produces zero testosterone change in men with pituitary adenomas or primary hypogonadism.
The bottom line for research applications: kisspeptin for testosterone is a diagnostic and investigational tool for understanding HPG axis regulation, not a general androgen enhancement compound. Its value lies in studying neuroendocrine control mechanisms, evaluating hypothalamic function in fertility disorders, and potentially restoring endogenous testosterone production in cases where the deficit is specifically hypothalamic. The peptide has no role in enhancing testosterone beyond physiological norms or in populations with normal baseline GnRH secretion.
We've synthesized Kisspeptin 10 using solid-phase peptide synthesis with exact amino-acid sequencing verified by mass spectrometry. Purity testing confirms >98% active peptide content with no detectable sequence errors or deamidation products. Research-grade kisspeptin for testosterone requires this level of synthesis precision because even minor impurities or sequence variations alter KISS1R binding kinetics and produce inconsistent dose-response curves. Our commitment to small-batch synthesis and third-party purity verification ensures every vial delivers the pharmacological properties documented in peer-reviewed studies.
The complexity of the HPG axis means kisspeptin for testosterone is one piece of a multi-step regulatory system. Evaluating its effects requires measuring GnRH (difficult in humans due to portal circulation), LH, FSH, testosterone, and often inhibin B and sex hormone-binding globulin to fully characterize the hormonal response. Single-endpoint testosterone measurements miss the upstream signals that reveal where the peptide is acting and whether the response is physiologically intact. This is why kisspeptin for testosterone research belongs in controlled laboratory settings where comprehensive hormonal profiling is feasible. The peptide's mechanism cannot be fully understood through isolated testosterone measurements alone.
Kisspeptin for testosterone represents a fundamental shift in how we study reproductive endocrinology. For decades, the field focused on downstream interventions. Administering LH analogs like hCG or direct testosterone replacement. Kisspeptin redirects attention to the master regulatory neurons that control the entire axis. Understanding how these neurons respond to metabolic signals, stress, and aging will define the next generation of fertility and androgen research. The peptide itself is a research tool that reveals how much we still don't understand about the neuroendocrine networks governing reproduction.
Frequently Asked Questions
How does kisspeptin for testosterone differ from taking exogenous testosterone or testosterone-boosting supplements?
▼
Kisspeptin for testosterone stimulates the body’s endogenous production pathway by activating GnRH neurons in the hypothalamus, which triggers pituitary LH and FSH release that signals the testes to synthesize testosterone naturally. Exogenous testosterone bypasses this system entirely and suppresses endogenous production through negative feedback — shutting down the HPG axis. Most testosterone-boosting supplements claim to enhance testicular steroidogenesis directly, but kisspeptin operates upstream at the neuroendocrine control level, making it mechanistically distinct from both replacement hormones and peripheral androgen enhancers.
Can kisspeptin for testosterone restore normal levels in men with low testosterone from steroid use?
▼
Not while exogenous androgens remain in the system. Supraphysiological testosterone from steroid use suppresses GnRH and LH secretion through androgen receptor-mediated negative feedback, rendering the pituitary refractory to kisspeptin stimulation. Kisspeptin for testosterone requires a washout period of 4–8 weeks after discontinuing exogenous steroids before the HPG axis regains responsiveness. Even then, recovery depends on whether testicular Leydig cells remain viable — prolonged steroid use can cause permanent Leydig cell atrophy, in which case kisspeptin will elevate LH but produce minimal testosterone response.
What is the typical dose range of kisspeptin-10 used in testosterone research, and how is it administered?
▼
Published human studies use kisspeptin-10 doses ranging from 0.3 to 10 nmol/kg, administered via intravenous or subcutaneous bolus injection. The most commonly cited effective dose for measurable LH and testosterone elevation is 1.0–4.0 nmol/kg, which corresponds to approximately 70–280 micrograms for a 70 kg individual. Peak LH response occurs 60–90 minutes post-injection, with testosterone levels rising 90–180 minutes after administration. Continuous infusion produces receptor desensitization, so research protocols favor intermittent pulsatile dosing to maintain gonadotropin responsiveness.
What side effects or adverse events have been reported in kisspeptin for testosterone studies?
▼
Clinical trials report minimal adverse events at standard research doses. The most common reported effect is mild injection site reaction (erythema, transient discomfort) in 10–15% of participants receiving subcutaneous administration. No significant cardiovascular, hepatic, or renal adverse events have been documented in Phase 1 or Phase 2 trials. One theoretical concern is excessive LH stimulation leading to testicular overstimulation or aromatization to estradiol, but controlled studies have not observed clinically significant estrogen elevations or testicular pain at doses up to 10 nmol/kg.
How does kisspeptin for testosterone compare to hCG (human chorionic gonadotropin) for restoring testosterone production?
▼
Kisspeptin for testosterone stimulates endogenous LH and FSH secretion from the pituitary, maintaining both spermatogenesis (FSH-dependent) and testosterone production (LH-dependent). hCG mimics LH directly by binding testicular LH receptors, stimulating testosterone synthesis without requiring pituitary involvement — but it does not stimulate FSH, which can impair spermatogenesis during long-term use. Kisspeptin preserves the natural pulsatile hormonal pattern and full gonadotropin secretion, while hCG provides a pharmacological LH analog. For fertility preservation, kisspeptin offers a more physiological approach; for rapid testosterone restoration, hCG acts faster.
Does kisspeptin for testosterone work in older men with age-related testosterone decline?
▼
Age-related testosterone decline (late-onset hypogonadism) typically involves both reduced hypothalamic GnRH secretion and diminished testicular Leydig cell responsiveness to LH. Kisspeptin for testosterone addresses the hypothalamic component — studies in men aged 50–70 show that kisspeptin-10 administration produces measurable LH increases, though the testosterone response is often 30–50% lower than in younger men with similar LH elevations. This suggests partial testicular hyporesponsiveness limits the efficacy. Kisspeptin for testosterone may partially restore androgen levels in aging males with predominantly hypothalamic deficiency, but it cannot fully compensate for primary gonadal aging.
What storage conditions are required for kisspeptin-10 to maintain peptide stability?
▼
Lyophilised kisspeptin-10 should be stored at −20°C in a sealed container protected from light and moisture. Once reconstituted with bacteriostatic water, store the solution at 2–8°C (standard refrigeration) and use within 14 days — peptide degradation accelerates beyond this timeframe. Temperature excursions above 8°C cause irreversible denaturation of the peptide structure, reducing KISS1R binding affinity by 30–60% within 48 hours. Never freeze reconstituted peptide solutions, as ice crystal formation disrupts peptide folding and aggregates the molecules into inactive forms.
Can kisspeptin for testosterone increase sperm production in men with infertility?
▼
Yes, in cases of hypogonadotropic hypogonadism where infertility results from insufficient FSH and LH secretion. Kisspeptin for testosterone stimulates both gonadotropins — LH drives testosterone synthesis in Leydig cells, while FSH supports Sertoli cell function and spermatogenesis in the seminiferous tubules. A 2018 study in men with idiopathic hypogonadotropic hypogonadism found that 12 weeks of twice-weekly kisspeptin-10 injections increased sperm concentration by 60% and improved sperm motility in participants with baseline oligospermia. The peptide does not improve sperm production in men with primary testicular failure or obstructive azoospermia.
Why does kisspeptin for testosterone produce no effect in men with pituitary tumors or pituitary damage?
▼
Kisspeptin for testosterone requires functional pituitary gonadotroph cells to produce LH and FSH in response to GnRH stimulation. Pituitary adenomas, surgical hypophysectomy, or radiation-induced pituitary damage destroy or compress gonadotroph populations, eliminating the cellular machinery that translates GnRH signals into gonadotropin secretion. In these cases, kisspeptin successfully stimulates hypothalamic GnRH release, but the pituitary cannot respond — LH and testosterone levels remain unchanged. This diagnostic pattern helps differentiate hypothalamic versus pituitary causes of hypogonadism in clinical research settings.
What happens if kisspeptin-10 is administered continuously rather than in pulsatile doses?
▼
Continuous kisspeptin-10 infusion causes KISS1R receptor desensitization on GnRH neurons, progressively reducing GnRH secretion despite sustained peptide levels. Studies show that LH response diminishes by 40–60% within 24 hours of continuous kisspeptin exposure, similar to the pituitary desensitization observed with continuous GnRH agonist therapy used in prostate cancer treatment. Pulsatile kisspeptin administration — intermittent bolus injections spaced 60–120 minutes apart — preserves receptor sensitivity and maintains robust LH secretion, mimicking the natural pulsatile firing pattern of endogenous kisspeptin neurons.
Is kisspeptin for testosterone being investigated as a potential treatment for male hypogonadism?
▼
Yes, Phase 2 clinical trials are evaluating kisspeptin-10 as a therapeutic option for idiopathic hypogonadotropic hypogonadism (IHH) and functional hypothalamic hypogonadism — conditions where testosterone deficiency results from impaired GnRH secretion rather than testicular or pituitary pathology. The peptide offers a potential alternative to traditional hCG and recombinant LH/FSH therapy by stimulating endogenous gonadotropin production. Regulatory approval would require Phase 3 efficacy and safety trials, but early results suggest kisspeptin for testosterone could provide a more physiological treatment approach for specific hypogonadal populations where the HPG axis remains structurally intact.
How quickly does testosterone return to baseline after a single kisspeptin-10 injection?
▼
Testosterone levels peak 90–180 minutes post-injection and return to baseline within 6–10 hours, depending on dose and individual metabolic clearance rates. The half-life of endogenously secreted LH (stimulated by kisspeptin) is approximately 20–30 minutes, so LH levels decline rapidly once kisspeptin is cleared. Testosterone synthesis continues for 60–90 minutes after LH peaks due to the enzymatic conversion lag, but once LH falls below the threshold for Leydig cell activation, testosterone production returns to baseline. This transient response distinguishes kisspeptin for testosterone from sustained androgen replacement therapies.
